1-18 of 18
Yan Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Jessica D. Sun, Qian Liu, Jingli Wang, Dharmendra Ahluwalia, Damien Ferraro, Yan Wang, Jian-Xin Duan, W. Steve Ammons, John G. Curd, Mark D. Matteucci, Charles P. Hart
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2287.
https://doi.org/10.1158/1078-0432.CCR-24-1058
Published: 15 May 2024
View article titled, Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Open the PDF for Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer in another window
Journal Articles

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients

Xiaojuan Zhou, Laiyan Zhou, Zhuoran Yao, Meijuan Huang, Youling Gong, Bingwen Zou, Jiang Zhu, Yongmei Liu, Feng Peng, Yan Zhang, Min Yu, Yanying Li, Feifei Na, Yijun Wu, Kai Kang, Weigang Xiu, Xuanwei Zhang, Lin Zhou, Yong Xu, Jin Wang, Yan Wang, Xue Yang, Yuanjun Wu, Rui Li, Yu Zhang, Zhenzhou Yang, Zhipeng Zhou, Jing Bai, Xin Yi, Ruizhan Tong, Limei Yin, Chong Chen, Gabriele Niedermann, You Lu, Jianxin Xue
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4098–4108.
https://doi.org/10.1158/1078-0432.CCR-23-0315
Published: 13 October 2023
View article titled, Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients
Open the PDF for Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1<sup>+</sup> Non–Small Cell Lung Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

Ibrahim Aldoss, Samer K. Khaled, Xiuli Wang, Joycelynne Palmer, Yan Wang, Jamie R. Wagner, Mary C. Clark, Jennifer Simpson, Jinny Paul, Vibhuti Vyas, Sheng-Hsuan Chien, Anthony Stein, Vinod Pullarkat, Amandeep Salhotra, Monzr M. Al Malki, Ahmed Aribi, Karamjeet Sandhu, Sandra H. Thomas, Lihua E. Budde, Guido Marcucci, Christine E. Brown, Stephen J. Forman
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 742–753.
https://doi.org/10.1158/1078-0432.CCR-22-2038
Published: 16 February 2023
View article titled, Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Open the PDF for Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL in another window
Includes: Supplementary data
Journal Articles

Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients

Wen Zhang, Caifeng Gong, Xuenan Peng, Xinyu Bi, Yongkun Sun, Jianguo Zhou, Fan Wu, Huiying Zeng, Yan Wang, Hui Zhou, Hong Zhao, Jianqiang Cai, Aiping Zhou
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3499–3508.
https://doi.org/10.1158/1078-0432.CCR-21-3972
Published: 15 August 2022
View article titled, Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Open the PDF for Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients in another window
Includes: Supplementary data
Journal Articles

Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study

Yuxi Yi, Lijun Shen, Wei Shi, Fan Xia, Hui Zhang, Yan Wang, Jing Zhang, Yaqi Wang, Xiaoyang Sun, Zhiyuan Zhang, Wei Zou, Wang Yang, Lingyi Zhang, Ji Zhu, Ajay Goel, Yanlei Ma, Zhen Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1329–1340.
https://doi.org/10.1158/1078-0432.CCR-20-3445
Published: 01 March 2021
View article titled, Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study
Open the PDF for Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study in another window
Includes: Supplementary data
Journal Articles

Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy

Katherine I. Zhou, Bryan Peterson, Anthony Serritella, Joseph Thomas, Natalie Reizine, Stephanie Moya, Carol Tan, Yan Wang, Daniel V.T. Catenacci
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (24): 6453–6463.
https://doi.org/10.1158/1078-0432.CCR-20-2085
Published: 15 December 2020
View article titled, Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Open the PDF for Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial

Xi Li, Li Zhang, Da Jiang, Yan Wang, Aimin Zang, Cuimin Ding, Min Zhao, Wuyun Su, Yan Zhang, Diansheng Zhong, Jin Wu, Cuiying Zhang, Guangyu An, Xingsheng Hu, Gang Cheng, Huaqing Wang, Yongqun Li, Xiaohui He, Junli Liu, Li Liang, Lieming Ding, Li Mao, Shucai Zhang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (13): 3162–3171.
https://doi.org/10.1158/1078-0432.CCR-19-3064
Published: 01 July 2020
View article titled, Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Open the PDF for Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial in another window
Includes: Supplementary data
Journal Articles

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

Eileen M. Boyle, Cody Ashby, Ruslana G. Tytarenko, Shayu Deshpande, Hongwei Wang, Yan Wang, Adam Rosenthal, Jeffrey Sawyer, Erming Tian, Erin Flynt, Antje Hoering, Sarah K. Johnson, Michael W. Rutherford, Christopher P. Wardell, Michael A. Bauer, Charles Dumontet, Thierry Facon, Sharmilan Thanendrarajan, Carolina D. Schinke, Maurizio Zangari, Frits van Rhee, Bart Barlogie, David Cairns, Graham Jackson, Anjan Thakurta, Faith E. Davies, Gareth J. Morgan, Brian A. Walker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2422–2432.
https://doi.org/10.1158/1078-0432.CCR-19-1507
Published: 15 May 2020
View article titled, <em>BRAF</em> and <em>DIS3</em> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Open the PDF for <em>BRAF</em> and <em>DIS3</em> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis

Yao Liu, Fanzheng Meng, Jiabei Wang, Mingyang Liu, Guangchao Yang, Ruipeng Song, Tongsen Zheng, Yingjian Liang, Shugeng Zhang, Dalong Yin, Jizhou Wang, Haiyan Yang, Shangha Pan, Bo Sun, Jihua Han, Jing Sun, Yaliang Lan, Yan Wang, Xirui Liu, Mingxi Zhu, Yifeng Cui, Bo Zhang, Dehai Wu, Shuhang Liang, Yufeng Liu, Xuan Song, Zhaoyang Lu, Jingxuan Yang, Min Li, Lianxin Liu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (17): 5407–5421.
https://doi.org/10.1158/1078-0432.CCR-18-4113
Published: 03 September 2019
View article titled, A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis
Open the PDF for A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis in another window
Includes: Supplementary data
Journal Articles

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Jianming Xu, Yun Zhang, Ru Jia, Chunyan Yue, Lianpeng Chang, Rongrui Liu, Gairong Zhang, Chuanhua Zhao, Yaoyue Zhang, Chunxia Chen, Yan Wang, Xin Yi, Zhiyuan Hu, Jianjun Zou, Quanren Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 515–523.
https://doi.org/10.1158/1078-0432.CCR-18-2484
Published: 15 January 2019
View article titled, Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Open the PDF for Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study in another window
Includes: Supplementary data
Journal Articles

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Zhe Yang, Nong Yang, Qiuxiang Ou, Yi Xiang, Tao Jiang, Xue Wu, Hua Bao, Xiaoling Tong, Xiaonan Wang, Yang W. Shao, Yunpeng Liu, Yan Wang, Caicun Zhou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (13): 3097–3107.
https://doi.org/10.1158/1078-0432.CCR-17-2310
Published: 01 July 2018
View article titled, Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Open the PDF for Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients in another window
Includes: Supplementary data
Journal Articles

PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Jian-Ming Xu, Yan Wang, You-Liang Wang, Yan Wang, Tao Liu, Ming Ni, Man-Sheng Li, Li Lin, Fei-Jiao Ge, Chun Gong, Jun-Yan Gu, Ru Jia, He-Fei Wang, Yu-Ling Chen, Rong-Rui Liu, Chuan-Hua Zhao, Zhao-Li Tan, Yang Jin, Yun-Ping Zhu, Shuji Ogino, Zhi-Rong Qian
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (16): 4602–4616.
https://doi.org/10.1158/1078-0432.CCR-16-2738
Published: 14 August 2017
View article titled, <em>PIK3CA</em> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Open the PDF for <em>PIK3CA</em> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract MIP-076: A RECURRENT BCAM-AKT2 FUSION GENE LEADS TO A CONSTITUTIVELY ACTIVATED AKT2 FUSION KINASE IN HIGH-GRADE SEROUS OVARIAN CARCINOMA

Kalpana Kannan, Cristian Coarfa, Pei-Wen Chao, Liming Luo, Yan Wang, Amy E. Brinegar, Shannon M. Hawkins, Aleksandar Milosavljevic, Martin M. Matzuk, Laising Yen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): MIP-076.
https://doi.org/10.1158/1557-3265.OVCASYMP16-MIP-076
Published: 31 May 2017
View article titled, Abstract MIP-076: A RECURRENT BCAM-AKT2 FUSION GENE LEADS TO A CONSTITUTIVELY ACTIVATED AKT2 FUSION KINASE IN HIGH-GRADE SEROUS OVARIAN CARCINOMA
Journal Articles

A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel

Jinhua Zhou, Albandri Alfraidi, Shu Zhang, Janice M. Santiago-O'Farrill, Venkata Krishna Yerramreddy Reddy, Abdulkhaliq Alsaadi, Ahmed A. Ahmed, Hailing Yang, Jinsong Liu, Weiqun Mao, Yan Wang, Hiroshi Takemori, Hariprasad Vankayalapati, Zhen Lu, Robert C. Bast, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 1945–1954.
https://doi.org/10.1158/1078-0432.CCR-16-1562
Published: 13 April 2017
View article titled, A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel
Open the PDF for A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel in another window
Includes: Supplementary data
Journal Articles

Abstract A22: Hypoxia-dependent antitumor activity of TH-302, a hypoxia-activated prodrug, in preclinical pancreatic xenograft models

Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia, Yan Wang, Fanying Meng, Deepthi Bhupathi, John G. Curd, Mark D. Matteucci, Charles P. Hart
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): A22.
https://doi.org/10.1158/1078-0432.TCMUSA10-A22
Published: 02 February 2016
View article titled, Abstract A22: Hypoxia-dependent antitumor activity of TH-302, a hypoxia-activated prodrug, in preclinical pancreatic xenograft models
Journal Articles

Abstract PR18: Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8, and IGF-1 in the tumor microenvironment.

Zhen Lu, Aaron F. Orozco, Hailing Yang, Margie N. Sutton, Yan Wang, Weiqun Mao, Douglas A. Levine, Robert C. Bast, Jr, Robert C. Bast, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): PR18.
https://doi.org/10.1158/1557-3265.OVCA15-PR18
Published: 15 January 2016
View article titled, Abstract PR18: Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8, and IGF-1 in the tumor microenvironment.
Journal Articles

IL-17A Stimulates the Progression of Giant Cell Tumors of Bone

Meng Xu, Zhi-Gang Song, Cheng-Xiong Xu, Guang-Hua Rong, Ke-Xing Fan, Ji-Ying Chen, Wei Zhang, Jin-Peng Jia, Gang Han, Wei Wang, Wei Chai, Wen-Tao Liang, Wen-Zhi Bi, Yan Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4697–4705.
https://doi.org/10.1158/1078-0432.CCR-13-0251
Published: 02 September 2013
View article titled, IL-17A Stimulates the Progression of Giant Cell Tumors of Bone
Open the PDF for IL-17A Stimulates the Progression of Giant Cell Tumors of Bone in another window
Includes: Supplementary data
Journal Articles

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

Jessica D. Sun, Qian Liu, Jingli Wang, Dharmendra Ahluwalia, Damien Ferraro, Yan Wang, Jian-Xin Duan, W. Steve Ammons, John G. Curd, Mark D. Matteucci, Charles P. Hart
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3): 758–770.
https://doi.org/10.1158/1078-0432.CCR-11-1980
Published: 01 February 2012
View article titled, Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Open the PDF for Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer in another window
Includes: Supplementary data